Struc­ture’s oral GLP-1 a ‘work in progress’ fol­low­ing Phase IIa obe­si­ty and di­a­betes da­ta

Phase IIa da­ta for Struc­ture Ther­a­peu­tics’ oral GLP-1 drug can­di­date for type 2 di­a­betes and obe­si­ty best­ed an­a­lyst ex­pec­ta­tions on safe­ty and tol­er­a­bil­i­ty, but low­er …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER